BR112012025854A2 - polimorfismo de um unico nucleotídeo que prevêem resultados para o tratamento do hcv. - Google Patents

polimorfismo de um unico nucleotídeo que prevêem resultados para o tratamento do hcv.

Info

Publication number
BR112012025854A2
BR112012025854A2 BR112012025854A BR112012025854A BR112012025854A2 BR 112012025854 A2 BR112012025854 A2 BR 112012025854A2 BR 112012025854 A BR112012025854 A BR 112012025854A BR 112012025854 A BR112012025854 A BR 112012025854A BR 112012025854 A2 BR112012025854 A2 BR 112012025854A2
Authority
BR
Brazil
Prior art keywords
single nucleotide
polymorphism
provides results
hcv treatment
hcv
Prior art date
Application number
BR112012025854A
Other languages
English (en)
Inventor
James Thommes
Laurent Essioux
Nancy Shulman
Soren Germer
Tom Chu
Uri Lopatin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR112012025854A2 publication Critical patent/BR112012025854A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

polimorfismo de um único nucleotídeo que prevêem resultados para o tratamento do hcv. a presente invenção se baseia das associações que existem entre os polimorfismos de um único nucleotídeo (snps) no cromossomo 4 e resultados virológicos em uma população diversa de pacientes com o vírus da hapatite c (hcv), os quais receberam tratamento à base de interferon.
BR112012025854A 2010-04-13 2011-04-11 polimorfismo de um unico nucleotídeo que prevêem resultados para o tratamento do hcv. BR112012025854A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32350210P 2010-04-13 2010-04-13
PCT/EP2011/055579 WO2011128278A1 (en) 2010-04-13 2011-04-11 Single nucleotide polymorphisms that predict hcv treatment outcomes

Publications (1)

Publication Number Publication Date
BR112012025854A2 true BR112012025854A2 (pt) 2017-01-10

Family

ID=44275673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012025854A BR112012025854A2 (pt) 2010-04-13 2011-04-11 polimorfismo de um unico nucleotídeo que prevêem resultados para o tratamento do hcv.

Country Status (12)

Country Link
US (1) US20120094389A1 (pt)
EP (3) EP2589670B1 (pt)
JP (1) JP5695181B2 (pt)
KR (1) KR101493137B1 (pt)
CN (1) CN102844448B (pt)
BR (1) BR112012025854A2 (pt)
CA (1) CA2795911A1 (pt)
ES (3) ES2525300T3 (pt)
HK (1) HK1180018A1 (pt)
MX (1) MX2012011804A (pt)
RU (1) RU2567663C2 (pt)
WO (1) WO2011128278A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130137084A1 (en) * 2011-11-28 2013-05-30 Roche Molecular Systems, Inc. Single Nucleotide Polymorphism on Chromosome 15 That Predicts HCV Treatment Responses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936694B1 (en) 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
US6824768B2 (en) * 1998-12-18 2004-11-30 Schering Corporation Ribavirin-pegylated interferon alfa induction HCV combination therapy
US7108978B2 (en) * 2003-07-15 2006-09-19 Vita Genomics, Inc. Method for detecting a propensity of an individual to respond effectively to treatment of interferon-α and ribavirin combined therapy
EP1591539B1 (en) * 2004-04-29 2007-10-03 F. Hoffmann-La Roche Ag NS5A nucleoside sequence variation as a marker
US20110270212A1 (en) * 2007-10-05 2011-11-03 Medtronic, Inc. Pharmacokinetic control for optimized interferon delivery

Also Published As

Publication number Publication date
CN102844448B (zh) 2015-11-25
WO2011128278A1 (en) 2011-10-20
ES2528899T3 (es) 2015-02-13
CA2795911A1 (en) 2011-10-20
HK1180018A1 (zh) 2013-10-11
CN102844448A (zh) 2012-12-26
ES2525290T3 (es) 2014-12-19
JP2013523168A (ja) 2013-06-17
EP2558592B1 (en) 2014-10-22
EP2558592A1 (en) 2013-02-20
EP2589670A1 (en) 2013-05-08
EP2589669A1 (en) 2013-05-08
MX2012011804A (es) 2012-12-17
EP2589669B1 (en) 2014-10-22
ES2525300T3 (es) 2014-12-19
KR101493137B1 (ko) 2015-02-12
JP5695181B2 (ja) 2015-04-01
RU2012145777A (ru) 2014-05-20
KR20130009842A (ko) 2013-01-23
RU2567663C2 (ru) 2015-11-10
US20120094389A1 (en) 2012-04-19
EP2589670B1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
CY1117574T1 (el) Αναλυση γονιδιωματικων κλασματων με χρηση των αριθμων πολυμορφισμων
BR112014008752A2 (pt) polimorfismos de nucleotídeos singulares úteis para predizer a resposta clínica para acetato de glatirâmero
BR112013002531A2 (pt) previsão dos cinéticos virais do hcv no tratamento livre de interferon
BR112014012886A2 (pt) um polimorfismo de nucleotídeo único no cromossoma 15 que prevê respostas ao tratamento de hcv
MX2017001908A (es) Metodo para el tratamiento de la depresion.
BR112012026124A2 (pt) previsão de resposta virológica precoce no tratamento de hcv
GT201300208A (es) Novedosos derivados de azabencimidazol cíclico útiles como agentes antidiabéticos
CL2011003129A1 (es) Procedimiento para determinar riesgo de padecer enfermedad cardiovascular que comprende determinar la presencia de polimorfismos de un solo nucleotido (snp)
UY35790A (es) Marcadores genéticos que predicen la respuesta al acetato de glatiramer
MX2017004127A (es) Metodos para evaluar el riesgo de desarrollar cancer de mama.
BR112012007684A2 (pt) embalagem do tipo bandeja e cobertura
BR112015018209A2 (pt) avaliação e recomendação em relação à nutrição e resistência
BR112013024880A2 (pt) seleção de tratamento de hcv
BR112015018973A2 (pt) avaliação e recomendação em relação à nutrição, resistência e força
BR112015000685A2 (pt) método para a identificação de risco clínico em um paciente possuindo ou suspeito de possuir uma infecção por influenza, método para a identificação de influenza ou pneumonia viral em um paciente, kit, método para avaliar a eficácia de um agente para o tratamento de influenza e para reduzir a severidade da doença em um indivíduo exposto a um vírus influenza.
BR112012025854A2 (pt) polimorfismo de um unico nucleotídeo que prevêem resultados para o tratamento do hcv.
NO20080221L (no) Cykloolefinkopolymer flaske med et skrapebestandig belegg
BR112013008511A2 (pt) tipagem com base em determinantes moleculares de alelos de kir e de ligantes de kir
WO2016149684A3 (en) Haplotype based generalizable allele specific silencing for therapy of cardiovascular disease
MX2016012718A (es) Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina.
Azimi et al. RETRACTED: Clinical significance of ITPA rs67002563 polymorphism in patients with acute lymphoblastic leukemia treated with 6-mercaptopurine
BR112017028488A2 (pt) métodos para tratar hcv
AR098142A1 (es) Marcadores genéticos que predicen la respuesta al acetato de glatiramer
UA109238C2 (ru) Способ выбора тактики лечения острого вирусного гепатита с
Boutorabi et al. Association of monoamine oxidase B and catechol-o-methyltransferase polymorphisms with sporadic parkinson’s disease in an Iranian population

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO ARQUIVAMENTO PUBLICADO NA RPI 2509 DE 05/02/2019.